Sean Javaheri, DO
Interventional Cardiology · Augusta, GANPI 1982677605
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $8,250 of the $13,116 with a category attached, or 62.9%. ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) accounts for 69.4% of it on its own, with 25 other manufacturers making up the rest. Reporting peaked in 2021 at $7,662 and has fallen 91.7% since, to $638 in 2025.
Across 96 payments — averaging $136.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$9K
- Medtronic$1K
- Abiomed$1K
- Abbott$287
- Inari Medical, Inc.$242
- Shockwave Medical, Inc$190
- plus $990 from 20 others
Across 27 payments — averaging $1452.97 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- CSL Behring$29K
- Abbott$10K
What the payments were for
- Speaking & faculty fees$8,25063%
- Travel & lodging$2592%
- Food & beverage$4,26333%
- Education$3433%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 19 | $9,105 |
| Medtronic(2 entities) | 15 | $1,245 |
| Abiomed | 10 | $1,058 |
| Abbott | 4 | $287 |
| Inari Medical, Inc. | 3 | $242 |
| Shockwave Medical, Inc | 4 | $190 |
| Stryker | 3 | $170 |
| Novartis | 7 | $136 |
| AstraZeneca | 3 | $133 |
| W. L. Gore & Associates, Inc. | 2 | $80 |
| Johnson & Johnson | 5 | $67 |
| Amgen | 3 | $66 |
| E.r. Squibb & Sons, L.L.C. | 2 | $40 |
| Pfizer | 2 | $38 |
| Cardiva Medical, Inc. | 2 | $35 |
| Philips North America LLC | 2 | $30 |
| Novo Nordisk | 1 | $28 |
| Esperion Therapeutics, Inc. | 1 | $25 |
| Boehringer Ingelheim | 1 | $23 |
| Actelion Pharmaceuticals US, Inc. | 1 | $23 |
| Scpharmaceuticals Inc. | 1 | $19 |
| Penumbra, Inc. | 1 | $18 |
| Asahi Intecc USA, Inc. | 1 | $17 |
| Biotronik Inc. | 1 | $16 |
| Astellas Pharma US Inc | 1 | $15 |
| Cardiovascular Systems Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LifeVest$8,609
- Impella$997
- AZURE XT DR MRI SURESCAN$316
- FlowTriever$248
- Azure$244
- FLOWTRIEVER CATHETER, S$216
- AMPLATZER Occluders$179
- ClotTriever$122
- Micra$103
How this compares
$13,116 in reported general payments places this provider in the 65th percentile of 218 interventional cardiology providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 189 | $198,181 |
| JardianceEmpagliflozin | 109 | $113,952 |
| EntrestoSacubitril/Valsartan | 92 | $103,635 |
| Repatha SureclickEvolocumab | 54 | $48,083 |
| TradjentaLinagliptin | 24 | $26,041 |
| XareltoRivaroxaban | 16 | $25,241 |
| FarxigaDapagliflozin Propanediol | 25 | $24,757 |
| Praluent PenAlirocumab | 29 | $23,887 |
| OzempicSemaglutide | 15 | $16,134 |
| Ezetimibe | 414 | $11,840 |
| Repatha SyringeEvolocumab | 15 | $9,680 |
| Metoprolol Succinate | 554 | $7,855 |
| Rosuvastatin Calcium | 372 | $5,030 |
| CorlanorIvabradine Hcl | 12 | $4,949 |
| Candesartan Cilexetil | 35 | $3,228 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $38 | $198,181189 claims |
| Boehringer IngelheimJardiance, Tradjenta | $23 | $139,993133 claims |
| NovartisEntresto | $136 | $103,63592 claims |
| Johnson & JohnsonXarelto | $67 | $25,24116 claims |
| AstraZenecaFarxiga | $133 | $24,75725 claims |
| Novo NordiskOzempic | $28 | $16,13415 claims |
| AmgenCorlanor | $66 | $4,94912 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 218 interventional cardiology providers in Georgia.
Other interventional cardiology in Augusta
- Charlene RohmAugusta$67K
- Musa SharkawiAugusta$30K
- Vishal AroraAugusta$22K
- William NicholsonAtlanta$1000K
- David KandzariAtlanta$982K
- Pradeep YadavAtlanta$656K
- Salvatore ManninoMarietta$275K
- Megan CoylewrightCalhoun$271K
- Paul GuichardMarietta$260K
- Adam GreenbaumAtlanta$238K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.